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Oral anticoagulation (OAC) is a highly effective means for the prevention of cardioembolic stroke but com-
plicated by an increased risk of intracerebral hemorrhage 
(ICH).1–3 OAC-associated ICH may occur either as primary 
ICH or as secondary hemorrhagic transformation of brain 
infarctions. To date, little is known about the optimal tim-
ing of OAC initiation relative to stroke onset. The uncertain 
risk of secondary ICH (sICH) frequently prevents clinicians 
from initiating OAC early after cardioembolic stroke. This 
increases the rate of recurrent thromboembolism at least in 
high-risk patients.4 Compared with vitamin K antagonists 
(VKA), such as warfarin or phenprocoumon, new oral anti-
coagulants, such as the direct thrombin inhibitor dabigatran 
etexilate (DE), exhibit reduced rates of intracranial hemor-
rhage,5,6 indicating a potentially better benefit/risk profile for 
stroke prevention.
Clinical trials addressing the occurrence of sICH depending 
on the timing of OAC initiation relative to stroke onset are 
currently not available and may be difficult to conduct without 
additional preclinical data. Genetic studies revealed strong 
evolutionary conservation of coagulation factors in vertebrates,7 
enabling an experimental approach to OAC-associated ICH 
in laboratory animals. A pivotal study in a mouse model of 
warfarin anticoagulation addressed the rate of sICH in animals 
already effectively anticoagulated at the time point of stroke 
induction. Hemorrhagic infarct transformation occurred in 
all anticoagulated mice within 24 hours of transient middle 
cerebral artery occlusion (tMCAO).8 However, more delayed 
stages of stroke lesion development were not addressed in 
this study. Regarding DE treatment, experimental findings in 
a model of primary ICH showed that in contrast to warfarin, 
pretreatment with DE did not increase hematoma volume 
within 24 hours after ICH induction.9 Furthermore, warfarin 
but not DE pretreatment increased the rate of thrombolysis-
associated sICH in the tMCAO model of ischemic stroke.10 
Thus, available evidence suggests a lower risk of hemorrhagic 
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complications under DE. However, only the hyperacute injury 
phase has been studied experimentally to date.
The mechanisms provoking or limiting sICH in various 
stages after the primary ischemic insult are largely unknown. 
Stroke-induced neuroinflammation may cause exacerbation 
of ischemic brain injury but may also foster repair and tis-
sue protection.11–16 Recently, we showed that hematogenous 
recruitment of monocyte-derived macrophages is a key mech-
anism of  brain repair in subacute stroke lesions, mainly via 
transforming growth factor-β–dependent stabilization of 
neovessels in the infarct border zone.17 We therefore postulated 
that interference with hematogenous macrophage recruitment 
may increase the risk of sICH after initiation of OAC early 
after ischemia. To address this issue, we first defined the tem-
poral risk profile of OAC-associated sICH under either VKA 
or DE treatment in a murine tMCAO model of moderate cere-
bral ischemia. To elucidate protective mechanisms counteract-
ing sICH, we then studied the impact of partial macrophage 
depletion on sICH occurrence in a delayed time window after 
ischemia.
Methods
Experimental procedures are detailed in the Supplementary Methods 
section. All animal experiments were approved by local authorities 
and were performed in accordance with international guidelines on 
handling laboratory animals. Focal cerebral ischemia was induced in 
male C57BL/6 mice by 55 minutes of tMCAO.18 Phenprocoumon or 
DE was administered via gastric tubing. In phenprocoumon-treated 
mice, international normalized ratio was determined at day 2 and day 
4 after initiation of OAC using a point-of-care device (CoaguChek; 
Roche, Basel, Switzerland). In DE-treated mice, activated partial 
thromboplastin time was monitored using standard laboratory test-
ing. Hematogenous macrophages were depleted by means of clodro-
nate-filled liposomes according to a previously described protocol.17 
Infarct volumes and bleeding rates were assessed on 2-mm-thick slic-
es stained with 2% 2,3,5-triphenyltetrazolium chloride. Bleeding vol-
umes were determined photometrically in supernatants of brain tissue 
homogenates. All analyses were performed by an investigator blind-
ed for treatment allocation, and results are presented as mean±SD. 
Statistical analyses were conducted using GraphPad Prism software 
(GraphPad Software Inc, La Jolla, CA).
Results
Blood Coagulation Parameters
In untreated mice, INR was 0.97±0.07 (n=9). Once-daily 
administration of 0.8 mg/kg phenprocoumon led to effective 
anticoagulation 48 hours later (INR 2.51±0.38, n=9), which 
could be maintained in a therapeutic range throughout the 
experiment (Figure 1A).
In mice treated with DE (Figure 1B), we used standard 
laboratory assessment of aPTT for establishment of a dose–
response curve over time. Thirty minutes after administration 
of DE at 75 mg/kg body weight, aPTT increased 2.5-fold above 
untreated controls (62.20±24.26 versus 25.14±3.9 seconds, 
n=5), decreasing to 1.59-fold at 8 hours (38.43±12.33 seconds, 
n=4), which is close to the mean aPTT elevation in humans in 
the steady state before administration of the next dose.19
Time-Dependent Risk of OAC-Associated sICH
We first performed macroscopic assessment of infarct devel-
opment and bleeding rate in tMCAO mice treated with 
phenprocoumon at various stages before or after ischemia 
induction (Figure 2A and 2B). When effective OAC was 
 present at the time point of stroke induction (ie, initiation of 
VKA treatment 2 days before tMCAO), 6 of 9 phenprocou-
mon-treated mice developed severe parenchymal hemorrhage 
and 3 of 9 developed hemorrhagic transformation. Hemorrhage 
was restricted to ischemic tissue areas. When effective OAC 
was achieved 48 hours after ischemia, 4 of 9 mice developed 
parenchymal hemorrhage and 3 of 9 developed hemorrhagic 
transformation. At both 72 and 96 hours, none of the mice 
developed parenchymal hemorrhage. Hemorrhagic transfor-
mation occurred in 5 of 10 mice in the 72-hour group and was 
absent in the 96-hour group.
In line with the macroscopic findings, photometrically 
determined blood volumes decreased from 11.0±4.5 µL (n=6) 
in mice effectively anticoagulated at the time of tMCAO 
to 5.1±4.2 µL (n=6) with OAC achieved at 48 hours and to 
3.5±1.5 µL (n=6) at 72 hours (Figure 2C). Effective OAC 
achieved at 96 hours was associated with very discrete hemor-
rhagic transformation (1 µL blood volume) in only 1 animal. 
Infarct volumes were not different between groups (effective 
OAC VKA d0, 88.5±31.93 mm3; VKA d2, 92.75±36.17 mm3; 
VKA d3, 85.86±30.59 mm3; VKA d4, 91.5±19.07 mm3).
Reduced Extent of sICH in DE-Treated Mice
For a comparative analysis of sICH under DE treatment, mice 
were started on DE at various time points before and after 
tMCAO. Compared with phenprocoumon treatment, mice 
pretreated with DE at a dose of 75 mg/kg body weight for 2 
days before tMCAO (corresponding to effective anticoagula-
tion with an aPTT of 38.43±12.33 seconds at the time point 
of stroke induction) showed a trend of decreased parenchymal 
hemorrhage with reciprocally increased hemorrhagic trans-
formation (Figure 3A). This qualitative finding was corrobo-
rated by a significant decrease in bleeding volume assessed 
photometrically in a separate experiment (11.0±4.5 µL in 
VKA-pretreated mice versus 3.8±3.5 µL in DE-pretreated 
mice, n=6; Figure 3B). Infarct volumes were not signifi-
cantly different between groups (VKA, 88.5±31.93 mm3; DE, 
82.67±22.25 mm3).
If effective anticoagulation was achieved 48 hours after 
ischemia (ie, DE treatment initiated 47 hours after tMCAO), none 
of the DE-treated mice developed parenchymal hemorrhage and 
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Figure 1. A, INR measurements at indicated time points after 
daily administration of phenprocoumon at 0.8 mg/kg body 
weight. Effective oral anticoagulation is achieved after 48 hours 
and maintained into later stages (n=9). B, After administration 
of dabigatran etexilate (DE) at a dose of 75 mg/kg body weight, 
aPTT increases within 30 minutes and reaches steady-state 
levels after 6 to 8 hours (n≥4, mean±SD). VKA denotes vitamin K 
antagonist.
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only 6 of 11 showed hemorrhagic transformation (Figure 3C). 
In photometric analysis, bleeding volume in the 48 hours 
group was also reduced in DE-treated versus phenprocoumon-
treated mice (0.8±1.0 µL versus 5.1±4.2 µL, n=6; Figure 3D). 
Infarct volumes were not different between groups (VKA, 
92.75±36.17 mm3; DE, 93.63±35.68 mm3). Rotarod testing 
performed at day 5 in mice effectively anticoagulated with 
either VKA or DE from 48 hours after stroke did not reveal 
significant differences in clinical outcome.
To elucidate the impact of intensity of OAC, we introduced 
an additional group of mice treated with a lower dose of phen-
procoumon (0.64 mg/kg) from day 0 after tMCAO, reaching 
effective OAC 48 hours after stroke (INR 2.24±0.28, n=9). In 
both dose groups, bleeding complications occurred to a similar 
extent (Figure 3C). Similarly, when all mice from both dose 
groups were pooled and stratified by INR range (INR 1.8–2.5 
versus INR 2.6–3.5), no differences between groups were evi-
dent. Thus, bleeding rates were independent from the intensity 
of OAC. We, furthermore, studied the effect of a higher dose 
of DE (112.5 mg/kg body weight). DE at 112.5 mg/kg caused 
a 2.76-fold elevation of the aPTT 6 hours later (66.68±25.21 
seconds, n=4), thereby resembling an overdose of DE in a 
clinical setting.19 In this high-dose DE-treated group, a high 
rate of severe sICH occurred, which was similar to the VKA-
treated groups (Figure 3C and 3D). Thus, supratherapeutic 
dosage of DE caused an increase in sICH comparable with 
VKA treatment, which is in line with previous findings in 
thrombolysis-associated infarct hemorrhage8 and collagenase-
induced hemorrhage.20
Partial Depletion of Hematogenous Macrophages 
Increases OAC-Associated sICH
Taken together, our results suggested the existence of a 
repair process that leads to a rapid decrease in the rate of 
OAC-associated sICH within 72 hours after tMCAO. In a 
recent study, we showed that depletion of monocyte-derived 
macrophages by means of clodronate-filled liposomes injected 
intraperitoneally at days 0 and 1 after tMCAO causes severe 
sICH of tMCAO-induced brain infarctions in nonanticoagu-
lated mice.17 To address a possible role of macrophages for the 
prevention of OAC-associated sICH, we chose a submaximal 
dose of clodronate liposomes (75% of maximum dose), which 
caused a less pronounced reduction of monocyte-derived 
macrophages in multicolor flow cytometric analysis of leu-
kocytes isolated from the infarctions (Figure 4A). In these 
analyses, hematogenous monocyte-derived macrophages 
were identified as CD11b-positive cells expressing high lev-
els of CD45 (CD45hi, as opposed to brain-resident microglia 
expressing intermediate levels of CD45) but not expressing 
the granulocyte marker Ly-6G. In the partially depleted mice, 
we observed only discrete hemorrhagic transformation but not 
severe parenchymal hemorrhage (Figure 4B). However, par-
tially depleted mice additionally started on phenprocoumon 
from 24 hours after tMCAO (ie, reaching effective anticoagu-
lation at day 3 after ischemia) exhibited a striking increase of 
parenchymal hemorrhage that exceeded the rate under either 
VKA or clodronate treatment alone (Figure 4B). Similar 
results were obtained in partially depleted mice effectively 
anticoagulated with DE at 48 hours after tMCAO (Figure 
4B). The increase in bleeding severity was paralleled by an 
increase in bleeding volume (Figure 4C). Thus, partial deple-
tion of monocyte-derived macrophages and OAC with either 
VKA or DE synergistically provoked sICH in subacute brain 
infarction.
Discussion
As a main finding, we show that the risk of sICH upon 
initiation of OAC early after tMCAO in mice rapidly decreases 
within 3 days of stroke onset, suggesting effective repair 
mechanisms that reestablish at least partial integrity of the 
neurovascular unit in early subacute stroke stages. Relative 
to VKA treatment, OAC with the direct thrombin inhibitor 
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Figure 2. A, Brain slices illustrating representative findings of parenchymal hemorrhage, hemorrhagic transformation, or absence of sec-
ondary intracerebral hemorrhage (sICH) after transient middle cerebral artery occlusion. Bar=5 mm, with ×2 magnifications shown on the 
right. B, Bleeding risk rapidly decreases with increasing latency between stroke onset and the day when effective oral anticoagulation 
(OAC) is achieved (n≥9). Black bars indicate parenchymal hemorrhage; gray bars, hemorrhagic transformation; and white bars absence of 
sICH. The time point of effective OAC relative to stroke onset is indicated on the x-axis. *P<0.05, **P<0.01 (χ2 test). C, Bleeding volumes 
also decrease with increasing latency from stroke onset (n=6). The whiskers  of the box-plot indicate the extreme values.
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DE is associated with a reduced risk of sICH both at the time 
of stroke onset and in the subacute stage of 48 hours after 
tMCAO. This finding is basically in line with the reduced rate 
of intracranial bleeding with DE treatment in clinical trials of 
stroke prevention, as well as with previous studies addressing 
DE effects in experimental ICH.5,6,9 Compared with these 
previous studies, our present study for the first time addressed 
the clinically relevant situation of OAC initiation early after 
ischemic stroke. In this subacute time window, clinicians are 
frequently faced with the therapeutic dilemma of reducing 
embolic stroke recurrence at the expense of increased 
intracranial bleeding complications, particularly in patients 
at high risk of thrombembolism. Our results indicate that the 
risk of sICH associated with classical VKA treatment may be 
relatively low beyond day 3 after the onset of ischemia and 
may be even lower with the newer anticoagulants, such as DE.
Regarding possible repair mechanisms, we have previously 
shown that extensive depletion of hematogenous macrophages 
using high-dose clodronate liposome treatment of nonantico-
agulated mice provokes a high rate of ≈50% parenchymal 
hemorrhage after tMCAO.17 The clodronate liposome tech-
nique is a well-characterized approach for specific depletion 
of phagocytic cells.21 Of note, clodronate liposomes do not 
deplete platelets but rather increase thrombopoietic activi-
ties, excluding that the observed bleedings are caused by a 
loss of platelets.22 In our previous study in nonanticoagulated 
mice, infarct hemorrhage after extensive macrophage deple-
tion occurred between days 2 and 3 after stroke onset,17 corre-
sponding to the temporal risk profile delineated in our present 
study. This suggested that macrophage-dependent brain repair 
may be involved in the prevention of OAC-associated sICH. 
To test this hypothesis, we reduced the liposome dose to a 
point where no overt bleeding was induced in nonanticoagu-
lated mice and combined this low-dose liposome regimen with 
phenprocoumon treatment from day 1 onward, normally also 
leading to only slight hemorrhagic transformation. Together, 
these 2 subthreshold conditions of macrophage depletion and 
anticoagulation synergistically increased the bleeding sever-
ity. Similar results were obtained with delayed DE treatment 
in macrophage-depleted mice, indicating that macrophage-
dependent repair processes are also essential for preventing 
sICH under the new anticoagulants.
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Figure 3. A, Comparison of mice treated with vitamin K antago-
nist (VKA; n=9) or dabigatran etexilate (DE; n=7) before transient 
middle cerebral artery occlusion (tMCAO) reveals a nonsignificant 
shift (χ2 test) from parenchymal hemorrhage toward hemorrhagic 
transformation in DE-pretreated animals. Black bars indicate 
parenchymal hemorrhage; gray bars, hemorrhagic transforma-
tion; and white bars absence of sICH. B, Significant reduction of 
bleeding volume after tMCAO in DE-pretreated versus VKA-pre-
treated mice (n=6). **P<0.01 (Student t test). C, If effective OAC 
is reached 48 hours after stroke onset, significantly lower bleed-
ing rates occur in DE-treated compared with VKA-treated mice. 
However, the difference is only evident at a DE dose of 75 mg/kg 
body weight but not at 112.5 mg/kg (n=9; *P<0.05 in χ2 test). In 
contrast to DE, bleeding pattern in VKA-treated mice is indepen-
dent from the dosage administered. D, Relative to VKA treatment, 
bleeding volume is likewise reduced with DE at 75 mg/kg but not 
at 112.5 mg/kg (n=6, *’P<0.05, Kruskal-Wallis test with the Dunn 
post hoc test). The whiskers of the box-plots throughout indicate 
the extreme values, and + indicates the mean.
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Figure 4. A, Flow cytometric analysis of 
hematogenous macrophages 72 hours 
after transient middle cerebral artery occlu-
sion. The full dose (100%) of clodronate 
liposomes (CloLip) strongly reduces mac-
rophage numbers in the infarctions. Less 
efficient reduction is observed with the 75% 
liposome dose. Bars denote mean±SD. 
B, Partial macrophage depletion alone, 
as well as effective oral anticoagulation 
(OAC) alone (either vitamin K antagonist 
[VKA] or dabigatran etexilate [DE]), causes 
only discrete hemorrhagic transformation 
of the infarctions. When delayed OAC and 
macrophage depletion are combined, high 
rates of severe parenchymal hemorrhage 
are found in both the VKA-treated and DE-
treated mice. Black bars indicate parenchymal hemorrhage; gray bars, hemorrhagic transformation; and white bars absence of sICH. *P<0.05, χ2 
test. C, Bleeding volumes are higher in macrophage-depleted and anticoagulated mice compared with each treatment alone (n=6). The whiskers 
of the box-plot indicate the extreme values, and + indicates the mean.
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Our findings are in line with accumulating evidence from 
other models of tissue injury describing profound impair-
ment of tissue repair and hemorrhagic complications after 
depletion of macrophages.23–25 Interestingly, bleeding into 
skin wounds of macrophage-depleted mice specifically 
occurred in a delayed time window after injury,24 comparable 
with our results. In contrast, most previous studies in stroke 
models focused on the acute stage of neuroinflammation, but 
did not specifically address the role of hematogenous mac-
rophages for delayed repair mechanisms.14,15 The critical rel-
evance of the time window was underscored by experiments 
addressing the role of matrix metalloproteinase-9 in neuro-
vascular remodeling after stroke.26 Although inhibition of 
matrix metalloproteinase-9 was beneficial in the early stage, 
delayed inhibition increased brain injury and—of particular 
importance for our study—caused hemorrhage into the isch-
emic area.
Under a translational perspective, several endogenous as 
well as exogenous factors can be envisaged to interfere with 
macrophage-dependent repair and thereby increase the risk 
of OAC-associated sICH in stroke patients. Diabetes mellitus 
and hyperglycemia are associated with a worse prognosis of 
ICH27,28 and an increased rate of hemorrhagic transformation 
after systemic thrombolysis in patients with ischemic stroke.29,30 
Although direct influences on the coagulation system may at 
least partially explain the increased bleeding risk,31 several 
studies showed that macrophage responses critical for wound 
healing are also impaired in diabetes mellitus.32,33 Regarding 
potential exogenous factors, cardiovascular drugs such as 
statins or angiotensin-II type 1 receptor blockers also interfere 
with macrophage recruitment into inflammatory tissue 
lesions.34,35 Although the pharmacological suppression of 
macrophage recruitment may be beneficial in atherosclerosis 
or autoimmunity, harmful effects causing disturbances in 
infarct demarcation and an increased bleeding risk after 
stroke also need to be considered and should be the subject 
of further study.
In conclusion, our study provides evidence that endogenous 
repair mechanisms involving hematogenous macrophages 
lead to a rapid decrease in the risk of OAC-associated sICH 
after ischemic stroke. Limitations of our study arise from the 
fact that it was conducted in young mice and that the impact 
of additional risk factors for OAC-associated ICH, in particu-
lar age and leukoaraiosis,36,37 was not specifically addressed. 
Therefore, studies incorporating additional risk factors are 
needed for a more complete understanding of OAC-related 
sICH in ischemic stroke.
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